BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Sabre//Sabre VObject 4.6.0//EN
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:Europe/Zurich
X-LIC-LOCATION:Europe/Zurich
TZURL:http://tzurl.org/zoneinfo/Europe/Zurich
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:19810329T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:19961027T030000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:news1771@biomedizin.unibas.ch
DTSTAMP;TZID=Europe/Zurich:20260630T140808
DTSTART;TZID=Europe/Zurich:20260710T140000
SUMMARY:Guest Speaker: Prof. Andres Floto is Professor of Respiratory Biolo
 gy at the University of Cambridge\, and Co-Director of the Cambridge Centr
 e for AI in Medicine (CCAIM)
DESCRIPTION:His basic research is focused on understanding: how bacteria ev
 olve from environmental organisms into specialist lung pathogens (Science
  2016\, 2021a\, 2021b\, 2024a\, 2024b\; Nature Microbiology 2021\, 
 2022\, 2025)\; how they interact with \,and are shaped by\, the innate im
 mune system (Science 2006\, 2014\; EMBO MM 2015\, Cell Reports 2025)
 \; and how functional genomics and machine learning can be combined with f
 ragment-based drug discovery to develop novel antibiotics (funded by Gates
  Foundation\, Wellcome Trust\, UK Cystic Fibrosis (CF) Trust\, US CF Found
 ation\, Shionogi\, GSK\, AZ). \\r\\nHis clinical research is centred arou
 nd novel therapies for Nontuberculous Mycobacteria (NTM) and Pseudomonas i
 nfections\, tackling chronic inflammation in CF and non-CF bronchiectasis\
 , and using AI to understand and predict pulmonary exacerbations (funded b
 y LifeArc & NIHR). Clinically he specialises in the management of Nontube
 rculous mycobacteria\, Cystic Fibrosis\, non-CF bronchiectasis\, and recur
 rent chest infections.
X-ALT-DESC:<p>His basic research is focused on understanding: how bacteria 
 evolve from environmental organisms into specialist lung pathogens (Scienc
 e&nbsp\;2016\,&nbsp\;2021a\,&nbsp\;2021b\,&nbsp\;2024a\,&nbsp\;2024b\;&nbs
 p\;Nature Microbiology&nbsp\;2021\, 2022\,&nbsp\;2025)\; how they interact
  with \,and are shaped by\, the innate immune system (Science&nbsp\;2006\,
 &nbsp\;2014\;&nbsp\;EMBO MM&nbsp\;2015\,&nbsp\;Cell Reports&nbsp\;2025)\; 
 and how functional genomics and machine learning can be combined with frag
 ment-based drug discovery to develop novel antibiotics (funded by Gates Fo
 undation\, Wellcome Trust\, UK Cystic Fibrosis (CF) Trust\, US CF Foundati
 on\, Shionogi\, GSK\, AZ).&nbsp\;</p>\n<p>His clinical research is centred
  around novel therapies for Nontuberculous Mycobacteria (NTM) and Pseudomo
 nas infections\, tackling chronic inflammation in CF and non-CF bronchiect
 asis\, and using AI to understand and predict pulmonary exacerbations (fun
 ded by LifeArc &amp\; NIHR).&nbsp\;Clinically he specialises in the manage
 ment of Nontuberculous mycobacteria\, Cystic Fibrosis\, non-CF bronchiecta
 sis\, and recurrent chest infections.</p>
DTEND;TZID=Europe/Zurich:20260710T150000
END:VEVENT
END:VCALENDAR